高级检索

低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的效果研究

谢函君, 邵克武

谢函君, 邵克武. 低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的效果研究[J]. 实用临床医药杂志, 2020, 24(7): 27-30. DOI: 10.7619/jcmp.202007008
引用本文: 谢函君, 邵克武. 低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的效果研究[J]. 实用临床医药杂志, 2020, 24(7): 27-30. DOI: 10.7619/jcmp.202007008
shu
XIE Hanjun, SHAO Kewu. Efficiency of low molecular heparin calcium combined with rivaroxaban in the treatment of elderly patients with advanced lung cancer complicated with pulmonary embolism[J]. Journal of Clinical Medicine in Practice, 2020, 24(7): 27-30. DOI: 10.7619/jcmp.202007008
Citation: XIE Hanjun, SHAO Kewu. Efficiency of low molecular heparin calcium combined with rivaroxaban in the treatment of elderly patients with advanced lung cancer complicated with pulmonary embolism[J]. Journal of Clinical Medicine in Practice, 2020, 24(7): 27-30. DOI: 10.7619/jcmp.202007008
shu

低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的效果研究

  • 湖北省仙桃市中医医院, 1. 内科;

  • 2. 肿瘤科, 湖北 仙桃, 433000

详细信息

  • 中图分类号: R734.2

Efficiency of low molecular heparin calcium combined with rivaroxaban in the treatment of elderly patients with advanced lung cancer complicated with pulmonary embolism

  • 1. Department of Internal Medicine;

  • 2. Department of Oncology, Xiantao Hospital of Traditional Chinese Medicine, Xiantao, Hubei, 433000

摘要

    摘要
  • 摘要: 目的 探讨低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞的临床效果。 方法 选取老年晚期肺癌合并肺栓塞患者84例,采用随机数字表法分为观察组与对照组各42例,对照组采用低分子肝素钙联合华法林治疗,观察组采用低分子肝素钙联合利伐沙班治疗, 2组均连续治疗3个月。比较2组临床疗效、治疗前后血气分析及凝血功能指标、不良反应发生情况。 结果 观察组疾病控制率(DCR)为85.71%, 高于对照组71.43%, 但差异无统计学意义(P>0.05)。治疗后, 2组患者动脉血氧分压［p(O2)］、血氧饱和度(SpO2)水平显著升高(P<0.05), 动脉血二氧化碳分压［p(CO2)］水平显著下降(P<0.05); 观察组治疗后p(O2)、SpO2水平显著高于对照组(P<0.05), p(CO2)水平显著低于对照组(P<0.05)。治疗后, 2组患者纤维蛋白原(FIB)、D-二聚体(D-D)水平显著下降(P<0.05), 凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)值显著升高(P<0.05); 观察组治疗后FIB、D-D水平显著低于对照组(P<0.05), PT、APTT值显著高于对照组(P<0.05)。治疗期间,观察组患者不良反应发生率为9.52%, 低于对照组的19.04%, 但差异无统计学意义(P>0.05)。 结论 低分子肝素钙联合利伐沙班治疗老年晚期肺癌合并肺栓塞疗效显著,能改善患者呼吸功能及凝血功能。
    Abstract: Objective To investigate the clinical efficacy of low molecular heparin calcium combined with rivaroxaban in the treatment of elderly patients with advanced lung cancer complicated with pulmonary embolism. Methods Totally 84 elderly patients with advanced lung cancer complicated with pulmonary embolism were selected and randomly divided into observation group and control group, with 42 cases in each group. The control group was treated with low molecular heparin calcium combined with warfarin, while the observation group was treated with low molecular heparin calcium combined with rivaroxaban. Clinical efficacy, indexes of blood gas analysis and coagulation function before and after treatment, and incidence of adverse reactions were compared between two groups. Results The disease control rate(DCR)of the observation group was 85.71%, which was higher than 71.43% of the control group(P>0.05). After treatment, the arterial oxygen partial pressure ［p(O2)］ and blood oxygen saturation(SpO2)levels significantly increased in both groups(P<0.05), the arterial carbon dioxide partial pressure ［p(CO2)］ level significantly decreased in both groups(P<0.05), and the p(O2)and SpO2 levels in the observation group were significantly higher than the control group(P<0.05), while the p(CO2)level was significantly lower than the control - group(P<0.05). After treatment, the levels of fibrinogen(FIB)and D-dimer(D-D)significantly decreased in both groups(P<0.05), the values of thrombinogen time(PT)and activated partial thromboplastin time(APTT)significantly increased in both groups(P<0.05), and the levels of FIB and D-D in the observation group were significantly lower than the control group(P<0.05), while the values of PT and APTT were significantly higher than the control group(P<0.05). During treatment, the incidence of adverse reactions in the observation group was 9.52%, which was lower than 19.04% in the control group(P>0.05). Conclusion The efficacy of low-molecular heparin calcium combined with rivaroxaban is effective in the treatment of elderly patients with advanced lung cancer complicated with pulmonary embolism, which can improve the respiratory and coagulation functions of patients.
    • HTML全文
    • 参考文献(15)

  • Attarian S, Rahman N, Halmos B. Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance[J]. Ann Transl Med, 2017, 5(18): 377-383.

    Socinski M A, Villaruz L C, Ross J. Understanding mechanisms of resistance in the epithelial growth factor receptor in non-small cell lung cancer and the role of biopsy at progression[J]. Oncologist, 2017, 22(1): 3-11.
    徐昆, 丁宇, 司全金. 利伐沙班对高龄老年急性静脉血栓治疗的有效性和安全性研究[J]. 中华老年多器官疾病杂志, 2016, 15(10): 729-733.
    中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组. 肺血栓栓塞症诊治与预防指南[J]. 中华医学杂志, 2018, 98(14): 1060-1087.
    梁柳丹, 林明宽, 周韶璋, 等. 利伐沙班联合低分肝素钙治疗晚期肺癌合并肺栓塞效果[J]. 中国老年学杂志, 2018, 38(18): 4385-4387.
    唐开华. 肺癌合并肺栓塞危险因素及预后的临床分析[J]. 临床肺科杂志, 2017, 22(8): 1477-1480.

    Mantha S, Laube E, Miao Y M, et al. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study[J]. J Thromb Thrombolysis, 2017, 43(2): 166-171.
    张春来, 黄炎明, 梁丽萍. 利伐沙班治疗肺栓塞20例临床疗效观察[J]. 中国实用医药, 2016, 11(29): 22-24.

    Lazo-Langner A, Fleet J L, McArthur E, et al. Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study[J]. J Thromb Haemost, 2014, 12(10): 1626-1635.
    柴海强. 利伐沙班联合低分子量肝素治疗急性肺栓塞的临床疗效及其对肺通气功能和血清Xa因子水平的影响[J]. 实用心脑肺血管病杂志, 2018, 26(3): 129-131.
    洪城, 高艺洋, 张萌, 等. 肺腺癌合并肺栓塞患者临床特征分析[J]. 国际呼吸杂志, 2017, 37(18): 1379-1383.

    Choe H K, De Sancho M T, Kim S S, et al. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies[J]. Blood Coagul Fibrinolysis, 2018, 29(2): 227-230.
    徐执政, 徐静, 郭军, 等. 低分子量肝素联合华法林治疗晚期肺癌合并急性非大面积肺栓塞的临床研究[J]. 健康研究, 2017, 37(1): 38-40.
    张敏霞. 低分子肝素钙联合利伐沙班治疗老年急性肺栓塞的临床疗效[J]. 实用心脑肺血管病杂志, 2018, 26(2): 114-118.
    唐开维, 莫桂清, 潘禹辰. 低分子肝素联合利伐沙班治疗急性肺栓塞的临床疗效[J]. 临床合理用药杂志, 2018, 11(15): 55-56.
    • 相关文章
    • 施引文献(18)

  • 期刊类型引用(18)

    1. 刘岩. 甲泼尼龙琥珀酸钠联合肾上腺素治疗过敏性休克患者的效果. 中国民康医学. 2024(09): 57-59 . 百度学术
    2. 鲍俊桥，王文涛. 甲泼尼龙琥珀酸钠治疗呼吸窘迫综合征患者的临床效果. 中国医药科学. 2024(13): 91-94 . 百度学术
    3. 王焕勤，王利芳. 吡非尼酮联合甲泼尼龙治疗特发性肺间质纤维化的效果及安全性分析. 河南医学研究. 2024(21): 3950-3953 . 百度学术
    4. 王国茗. 甲泼尼龙联合丙卡特罗对支气管哮喘患者肺功能及炎症反应的影响. 中国药物经济学. 2023(01): 78-81 . 百度学术
    5. 颜海峰，霍开明，林裕庆，周家仍. 血清KLF2、Ang1水平与新生儿呼吸窘迫综合征严重程度及预后的相关性分析. 国际检验医学杂志. 2023(24): 2996-3000 . 百度学术
    6. 李莎雯. 注射用甲泼尼龙琥珀酸钠联合特布他林雾化吸入治疗慢性支气管炎急性发作期的效果及安全性分析. 医学信息. 2022(20): 77-79+83 . 百度学术
    7. 何元勇，罗锦秀. 甲泼尼龙琥珀酸钠联合呼吸兴奋剂在慢性阻塞性肺疾病合并呼吸衰竭中的应用. 中国卫生标准管理. 2022(22): 147-151 . 百度学术
    8. 王春刚，王志峰，颜洪顺. 侧卧位通气与机械振动排痰对ARDS患者呼吸指标、炎症指标的影响. 中外医学研究. 2021(01): 156-158 . 百度学术
    9. 赵振波，刘雨婷，常高兰. 注射用甲泼尼龙琥珀酸钠对急性呼吸衰竭患者动脉血气及呼吸力学的影响. 黑龙江医学. 2021(07): 741-742 . 百度学术
    10. 郝学斌，王雅宁，任志慧，曹丽林. 无缝隙管理模式对重症急性呼吸窘迫综合征患者的应用价值. 河北医药. 2021(14): 2171-2174 . 百度学术
    11. 温小媚. 复苏合剂联合注射用甲泼尼龙治疗中重度急性呼吸窘迫综合征临床研究. 新中医. 2021(13): 61-64 . 百度学术
    12. 邓菁，薛珍，游荣枫. 专职化护理模式对急性呼吸窘迫综合征患儿血气指标及预后的影响. 中国现代医生. 2021(23): 185-188 . 百度学术
    13. 罗宁，许明，郑亮，倪荣，孙敏敏，杨桦，韩双双，芦乙滨. 早期高容量血液滤过治疗重症急性胰腺炎伴急性呼吸窘迫综合征患者的效果. 河南医学研究. 2021(32): 6006-6009 . 百度学术
    14. 胡小丹. 注射用甲泼尼龙琥珀酸钠联合氨茶碱对急性呼吸衰竭患者动脉血气及呼吸力学的影响. 当代医学. 2021(36): 159-160 . 百度学术
    15. 徐仕霞. 无创高频震荡通气联合肺表面活性物质治疗新生儿呼吸窘迫综合征的临床研究. 实用临床医药杂志. 2020(08): 29-32 . 本站查看
    16. 马旭涛，赵蒙. 肺超声评分对新生儿呼吸窘迫综合征严重程度的评估价值. 河南医学研究. 2020(26): 4947-4949 . 百度学术
    17. 胡丽娟. 注射用甲泼尼龙琥珀酸钠辅治呼吸窘迫综合征的效果. 临床合理用药杂志. 2020(29): 41-42 . 百度学术
    18. 谢鹏. 两种药物联合治疗慢性喘息性支气管炎的疗效. 深圳中西医结合杂志. 2020(21): 174-175 . 百度学术

    其他类型引用(0)

    • 资源附件(0)
计量
  • 文章访问数:  393
  • HTML全文浏览量:  87
  • PDF下载量:  12
  • 被引次数: 18
出版历程
  • 收稿日期:  2020-01-01

目录

摘要
HTML全文
    参考文献(15)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    x 关闭 永久关闭